Lung cancer drugs

These companies develop drugs for lung cancer, often targeting genes like EGFR, ALK, ROS1, MET or KRAS.
−22.1%
over 1 month · S&P 500 −2.3%

Key indicators

Health
50 / 100
Fragile
Solid
Up over 1 year
3 of 8
Volatility
82%
Calm
Choppy
Profitability
−65%
Low
High
Health and price: against the other tags.